Greenwich Issuance Purchase of Equity Shares vs Share Based Compensation Analysis

GLSI -  USA Stock  

USD 8.48  0.07  0.83%

Greenwich Lifesciences financial indicator trend analysis is much more than just examining Greenwich Lifesciences latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Greenwich Lifesciences is a good investment. Please check the relationship between Greenwich Lifesciences Issuance Purchase of Equity Shares and its Share Based Compensation accounts. Please check Risk vs Return Analysis.

Issuance Purchase of Equity Shares vs Share Based Compensation

Issuance Purchase of Equity Shares vs Share Based Compensation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Greenwich Lifesciences Issuance Purchase of Equity Shares account and Share Based Compensation. At this time, the significance of the direction appears to have pay attention.
The correlation between Greenwich Lifesciences' Issuance Purchase of Equity Shares and Share Based Compensation is -0.76. Overlapping area represents the amount of variation of Issuance Purchase of Equity Shares that can explain the historical movement of Share Based Compensation in the same time period over historical financial statements of Greenwich Lifesciences, assuming nothing else is changed. The correlation between historical values of Greenwich Lifesciences' Issuance Purchase of Equity Shares and Share Based Compensation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Issuance Purchase of Equity Shares of Greenwich Lifesciences are associated (or correlated) with its Share Based Compensation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Share Based Compensation has no effect on the direction of Issuance Purchase of Equity Shares i.e., Greenwich Lifesciences' Issuance Purchase of Equity Shares and Share Based Compensation go up and down completely randomly.

Correlation Coefficient

-0.76
Relationship DirectionNegative 
Relationship StrengthWeak

Issuance Purchase of Equity Shares

A component of Net Cash Flow from Financing representing the net cash inflow (outflow) from common equity changes. Includes additional capital contributions from share issuances and exercise of stock options; and outflow from share repurchases.

Share Based Compensation

A component of Net Cash Flow from Operations representing the total amount of noncash; equity-based employee remuneration. This may include the value of stock or unit options; amortization of restricted stock or units; and adjustment for officers' compensation. As noncash; this element is an add back when calculating net cash generated by operating activities using the indirect method.
Most indicators from Greenwich Lifesciences fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Greenwich Lifesciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Please check Risk vs Return Analysis.The current Issuance Purchase of Equity Shares is estimated to increase to about 3.2 M, while Selling General and Administrative Expense is projected to decrease to roughly 992.8 K.

Greenwich Lifesciences fundamental ratios Correlations

Greenwich Lifesciences Account Relationship Matchups

Be your own money manager

Our tools can tell you how much better you can do entering a position in Greenwich Lifesciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Holdings Now

   

Portfolio Holdings

Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Greenwich Lifesciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Note that the Greenwich Lifesciences information on this page should be used as a complementary analysis to other Greenwich Lifesciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Greenwich Stock analysis

When running Greenwich Lifesciences price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Is Greenwich Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
109.3 M
Return On Assets
-0.15
Return On Equity
-0.24
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Greenwich Lifesciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.